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OBJECTIVES This study evaluated the early outcomes of patients with acute coronary syndromes (ACS)
treated with sirolimus-eluting stents (SES).
BACKGROUND The safety of SES implantation in patients with a high risk for early thrombotic complica-
tions is currently unknown.
METHODS Sirolimus-eluting stents have been utilized as the device of choice for all percutaneous
procedures in our institution, as part of the Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospital (RESEARCH) registry. After four months of enrollment,
198 patients with ACS had been treated exclusively with SES (64% of those treated in the
period) and were compared with a control group composed of 301 consecutive patients
treated with bare stents in the same time period immediately before this study. The incidence
of major adverse cardiac events (MACE) during the first month was evaluated (death,
nonfatal myocardial infarction [MI], or re-intervention).
RESULTS Compared with control patients, patients treated with SES had more primary angioplasty
(95% vs. 77%; p  0.01), more bifurcation stenting (13% vs. 5%; p  0.01), less previous MI
(28% vs. 45%; p  0.01), and less glycoprotein IIb/IIIa inhibitor utilization (27% vs. 42%;
p  0.01). The 30-day MACE rate was similar between both groups (SES 6.1% vs. control
patients 6.6%; p  0.8), with most complications occurring during the first week. Stent
thrombosis occurred in 0.5% of SES patients and in 1.7% of control patients (p  0.4). In
multivariate analysis, SES utilization did not influence the incidence of MACE (odds ratio
1.0 [95% confidence interval: 0.4 to 2.2]; p  0.97).
CONCLUSIONS Sirolimus-eluting stent implantation for patients with ACS is safe, with early outcomes
comparable with bare metal stents. (J Am Coll Cardiol 2003;41:2093–9) © 2003 by the
American College of Cardiology Foundation
Percutaneous intervention has been increasingly demon-
strated to reduce the risk of adverse events in patients with
acute coronary syndromes (ACS) (1,2). Several technical
and medical advancements have contributed to improve the
results of angioplasty in this population. However, patients
with acute coronary disease still present a higher risk for
early events than chronic stable patients, possibly owing to
an increased propensity for thrombotic complications in the
first days after the intervention (3–5).
Sirolimus-eluting stent (SES) implantation has been
demonstrated to virtually abolish in-stent restenosis in
elective patients with relatively simple lesions (6,7). Nota-
bly, the reduction of in-stent restenosis with SES was
achieved without compromising the high acute success rates
currently accomplished with bare stents. However, the
impact of SES in unselected complex cases is presently not
known. Sirolimus has been reported to decrease endothelial
function in vitro (8) and to affect platelet physiology (9–11).
Moreover, impaired local vascular healing with delayed
endothelization and late fibrin persistence has not been
ruled out after SES implantation (12,13). Therefore, eval-
uation of the safety of SES in patients with increased risk
for early thrombotic events is warranted.
The aim of this study was to investigate the impact of
SES implantation on the occurrence of early adverse events
(30 days) in a consecutive series of unselected patients with
ACS enrolled in the Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospital (RESEARCH) registry.
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METHODS
The RESEARCH registry. The SES (Cypher; Johnson &
Johnson-Cordis unit, Cordis Europa NV, Roden, the Neth-
erlands) received Conformite´ Europe´enne mark approval in
April 2002, since then being commercially available for
routine use in Europe. From April 16, 2002, it has been our
policy to utilize the SES as the device of choice for every
percutaneous coronary intervention performed in our insti-
tution, as part of the RESEARCH registry. The
RESEARCH is a single-center registry conducted with the
aim of evaluating the impact of SES implantation in the
“real world” of interventional cardiology. All consecutive
procedures were included, without any specific anatomical
or clinical restriction. Additionally, a control group was
formed by all patients treated with percutaneous interven-
tions in the period immediately before this study. Therefore,
the control and the RESEARCH groups are constituted by
two sequential cohorts, primarily defined by the interven-
tional strategy applied (conventional bare stent or SES
implantation, respectively).
All procedures were performed according to standard
interventional techniques except by the utilization of SES as
the device of choice during the RESEARCH period (at the
initiation of the RESEARCH registry, SES were available
in diameters from 2.25 to 3.00 mm and lengths of 8, 18, and
33 mm). Glycoprotein IIb/IIIa inhibitors were given at the
discretion of the operator.
The postprocedural antiplatelet regimen consisted of
aspirin lifelong and clopidogrel 75 mg/day for one month
(control group and patients treated with bare stent only) or
three months (patients treated with SES). Prolonged clo-
pidogrel prescription (six months) was recommended for
patients treated with SES and at least one of the following
characteristics: multiple SES (3 stents), total stented
length 36 mm, chronic total occlusion, bifurcations, and
in-stent restenosis.
During the RESEARCH period, according to the actual
SES utilization, three subgroups were a priori expected: 1)
patients treated only with SES; 2) patients in whom both a
SES and a non-SES device were utilized at the index
procedure; and 3) patients treated without implantation of
any SES. The specific reasons for nonutilization of SES
were registered on a lesion-per-lesion basis.
The RESEARCH registry was designed with the pri-
mary objective of evaluating the effectiveness of SES im-
plantation compared with the control population. Effective-
ness in both groups was measured by the survival time
during which patients remain free of major adverse cardiac
events (MACE) after one year of follow-up. Additionally,
the following secondary objectives have also been pre-
defined: 1) short-term (30-day) safety in patients with ACS;
2) survival free of MACE at six-month follow-up; 3)
cost-effectiveness analysis at six months and one year; 4)
anginal status and medication usage at six months and one
year; and 5) quality of life and work status at six months and
one year.
In the present study, we report on the 30-day outcomes of
patients with ACS treated with SES implantation com-
pared with the control population. This study protocol was
approved by the local ethics committee and is in accordance
with the principles of Good Clinical Practice for Trials of
Medicinal Products in the European Community and the
Declaration of Helsinki. Written, informed consent was
given by every patient.
ACS substudy: patient population. In the present report,
we evaluated the 30-day outcomes of all 198 consecutive
patients with unstable angina or acute myocardial infarction
(MI) treated exclusively with SES during the first four
months of the RESEARCH registry (from April 16, 2002
to August 15, 2002). This group represents 64% of all
procedures performed in patients with ACS in the period
(n  311 patients). Patients receiving both bare stents and
SES in the same procedure (32 patients; 10%) and those
treated without SES implantation (81 patients; 26%) were
not included in the present analysis. Among patients not
included, nonutilization of SES was due to unavailability of
an appropriate SES size (diameter or length) in 73% of
cases, inclusion in another study in 5%, and impossibility to
cross the lesion with the SES in 1%. In the remaining 21%
of cases, SES was not utilized owing to a variety conditions
related to the operator’s personal choice or other “medical/
technical issues” (for instance, balloon dilation instead of
stent implantation in a small coronary branch, mechanical
thrombectomy without stent implantation for vessels with a
high thrombotic burden, or heparin-coated stents owing to
contraindication for antiplatelet therapy). A control group
was comprised of 301 consecutive patients with ACS
treated with bare stent implantation during the last four
months (from December 16, 2001 to April 15, 2002) before
the initiation of the RESEARCH registry (94% of all
patients treated in the period). Patients with unstable angina
were categorized according to the Braunwald classification
(14). Procedures performed in the first 24 h of an acute MI
were classified as rescue or primary angioplasty, if preceded
or not by (failed) intravenous thrombolysis, respectively.
Patients treated after 24 h but before discharge of an episode
of MI were classified as post-MI unstable angina (Braun-
wald class C).
End point definitions and follow-up. Major adverse car-
diac events were defined as: 1) death; 2) nonfatal MI; or 3)
Abbreviations and Acronyms
ACS  acute coronary syndromes
CI  confidence interval
MACE  major adverse cardiac events
MI  myocardial infarction
OR  odds ratio
RESEARCH  Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospital registry
SES  sirolimus-eluting stent
TIMI  Thrombolysis In Myocardial Infarction
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repeat target lesion revascularization or target vessel revas-
cularization. A definite diagnosis of MI required an increase
in the creatine kinase level to more than twice the upper
normal limit with an increased level of creatine kinase-MB
(7). Target lesion revascularization was defined as any
surgical or percutaneous re-intervention motivated by a
significant luminal narrowing within the stent or in the
5-mm distal or proximal peristent segments. Target vessel
revascularization was defined as any re-intervention driven
by lesions located in the treated vessel even beyond the
target lesion limits. Additionally, we analyzed the incidence
of stent thrombosis, defined as any angiographically docu-
mented thrombotic occlusion (Thrombolysis In Myocardial
Infarction [TIMI] flow grade 0 or 1) or flow-limiting
thrombus (TIMI flow grade 1 or 2) occurring after the
procedure (after removal of the guiding catheter) in an
artery treated with angiographic success (TIMI flow grade 3
immediately after stent placement and percent in-lesion
diameter stenosis 30%).
All procedures were performed in a tertiary cardiology
center. As ruled by the local medical system organization,
the majority of hospitalized patients treated in this tertiary
facility were referred from other peripheral hospitals, to
which they were discharged shortly after the procedure
unless a periprocedural complication occurred and/or spe-
cialized surveillance was required. In total, patients have
been referred from a group of 14 local hospitals. Postpro-
cedure medical care was performed at the discretion of the
site of origin. Cardiac enzymes were measured serially after
the procedure for all in-hospital patients maintained in our
hospital. In most of the peripheral hospitals, cardiac markers
were not collected routinely, unless a postprocedure MI was
suspected. For elective outpatient cases, it has been our
practice to discharge the patients after a mean period of
observation of 3  1 h (unpublished data), provided no
postprocedural complications had occurred (access site he-
mostasis was routinely performed with a femoral closure
device whenever possible). As a result of these policies for
in- and outpatient cases, serial cardiac markers were not
available only for patients in whom the likelihood of
postprocedure MI was judged to be low. Such policy has
been supported by evidence from studies with large popu-
lation cohorts showing that minor asymptomatic enzymatic
elevation has no impact on either short- or long-term
prognosis (15,16) and, therefore, is highly unlikely to
influence the postprocedural medical conduct.
In-hospital outcome information was obtained by means
of an electronic clinical database for patients maintained in
our hospital after the procedure and by review of the
hospital records for those discharged to secondary hospitals.
During the follow-up, recordings of all repeat interventions
(surgical and percutaneous) and re-hospitalizations were
prospectively collected in a dedicated database. Long-term
survival status was assessed by written inquiries to the
Municipal Civil Registries at 30 days, 6 months, and 1 year
after the procedures. Questionnaires were sent at six months
and one year to all living patients with information regard-
ing postdischarge anginal status, medication usage, and the
occurrence of clinical events. Furthermore, a psychological
questionnaire was sent and included forms with the Short
Form-36 quality of life (17), the Hospital Anxiety and
Depression Scale (18), and the Type D personality score
(19). The referring physician and institutions as well as the
general practitioners were directly approached whenever
necessary for additional information. For patients who went
abroad, an effort was made to contact the local civil registries
of their new residencies. Patients lost to follow-up were
considered at risk until the date of last contact, at which
point they were censored.
Data management and statistical analysis. All consecu-
tive procedures were included in the control group and in
the RESEARCH, utilizing a dynamic registry design as
previously described by Rothman and Greenland (20). For
each patient, the time until the first MACE was computed
(person-time). Any eventual repeat percutaneous interven-
tion acts then as a new index procedure, and the person-
time contributes again to the cohort. Therefore, a patient
can contribute to one, two, or more person-time. This
design is of particular interest in a study like the
RESEARCH, which intends to evaluate two consecutive
cohorts treated with coronary angioplasty. If re-entry is not
allowed, the second group (in the present case, treatment
with SES) is consequently emptied from cases with treat-
ment for restenotic lesions. This design, therefore, permits
the inclusion of patients with in-stent restenosis in both
study periods, allowing the evaluation of the impact of each
particular re-intervention on the subsequent outcomes. In
view of the small applicability of this concept (person-time
analysis) for short-term evaluations, no calculations with
person-time units were performed in the current ACS
substudy.
Discrete variables were presented as percentages and
compared with Fisher exact tests. Continuous variables were
presented by their means and standard deviations and
compared with Student t test or one-way analysis of
variance. Cumulative survival and MACE-free survival were
calculated according to the Kaplan-Meier method. The
log-rank test was used to compare survival and MACE-free
survival among the different groups. Multivariate indepen-
dent predictors of 30-day outcomes were evaluated by
logistic regression. All baseline and procedural characteris-
tics presented in Table 1 were tested, and a final multivariate
model was constructed by backward deletion of the least
significant variables. All tests were two-tailed, and a p value
of 0.05 was considered as significant.
RESULTS
Baseline and procedural characteristics. Clinical and pro-
cedural characteristics of the 499 patients included in the
present report are summarized in Table 1. As compared
with the control patients, patients treated with SES had
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more frequently primary angioplasty (95% vs. 77%; p 
0.01), more bifurcation stenting (13% vs. 5%; p 0.01), less
previous MI (28% vs. 45%; p  0.01), and less glycoprotein
IIb/IIIa inhibitor utilization (27% vs. 42%; p 0.01) (Table
1). Also, peak creatine kinase-MB was lower for acute MI
patients treated with SES (217  236 U/l vs. 317  256
U/l; p  0.04) (Table 1). Procedural angiographic success
was achieved in all attempted lesions in a similar proportion
of cases in the SES and the control groups (96% vs. 97%,
respectively, p  0.48) (Table 1).
30-day outcome. The 30-day outcomes of the SES and
control groups are shown in Table 2. Complete follow-up
information was available for all patients in the SES group
and for all except one patient in the control group (99.7%).
There were no differences in the incidence of adverse events
between patients treated with bare stents and those treated
with SES (30-day MACE rate 6.1% vs. 6.6%, respectively;
p  0.8 by log-rank test), with most complications occur-
ring in the first week after the procedure (Fig. 1). Stent
thrombosis occurred in one patient (0.5%) in the SES group
and in five patients (1.7%) in the control group (p  0.4)
(Table 2). We performed a multivariate analysis to deter-
mine independent predictors of MACE at 30 days. Figure
2 shows the four significant predictors of 30-day MACE
identified in the final model. The presence of multivessel
disease (odds ratio [OR] 4.4 [95% confidence interval {CI}:
1.8 to 10.8]; p 0.01), cardiogenic shock (OR 3.9 [95% CI:
1.2 to 12.8]; p  0.02), and acute MI at presentation (OR
3.3 [95% CI: 1.4 to 7.6]; p  0.01) were associated with an
increased risk of MACE, while right coronary angioplasty
Table 1. Baseline and Procedural Characteristics of Patients Treated With Bare Stents Versus




(n  198) p Value
Age, yrs, mean  SD 60  12 62  11 0.21
Male gender, % 75 68 0.10
Diabetes, % 12 18 0.07
Hypercholesterolemia 48 49 0.93
Current smoking, % 38 38 0.85
Hypertension, % 63 63 0.93
Previous MI, % 45 28  0.01
Previous angioplasty, % 18 21 0.56
Previous CABG, % 10 9 0.64
Coronary artery disease, % 0.12
Single-vessel disease 44 51
Multivessel disease 56 49
Unstable angina, % 68 68 1.0
Braunwald classification, %*
Class I to III-A 5 4 0.61
Class I and II-B 45 42 0.65
Class III-B 21 22 0.78
Class I and II-C 14 9 0.23
Class III-C 15 22 0.12
Acute MI, % 32 32 1.0
Cardiogenic shock† 13 13 1.0
Rescue angioplasty† 23 5  0.01
Primary angioplasty† 77 95  0.01
Peak CK-MB, U/l  SD‡ 317  256 217  236 0.04
Glycoprotein IIB/IIIA inhibitor, % 42 27  0.01
Vessel treated, %
LMC 3 4 0.60
LAD 58 59 0.85
LCx 31 29 0.69
RCA 39 36 0.64
Bypass 6 5 0.84
Lesion type A/B1, % 42 44 0.71
Lesion type B2/C, % 78 78 1.0
Number of treated segments ( SD) 1.8  0.9 1.8  0.9 1.00
Total stented length, mm  SD 28  13 29  15 0.30
Bifurcation stenting 5 13  0.01
Angiographic success of all lesions, % 97 96 0.48
*Relative to the number of patients with unstable angina; total sum may not result in 100% because of rounding; †relative to the
number of patients with acute MI; ‡upper limit of normal  24 U/l.
CABG  coronary artery bypass graft surgery; CK  creatine kinase; LAD  left anterior descending artery; LCx  left
circumflex artery; LMC  left main coronary; MI  myocardial infarction; RCA  right coronary artery; SES 
sirolimus-eluting stent.
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(OR 0.4 [95% CI: 0.2 to 0.9]; p  0.04) was related to a
decrease in the odds of early adverse events. When forced
into the model, SES utilization (OR 1.0 [95% CI: 0.4 to
2.2]; p  0.97) did not predict the occurrence of adverse
events, with virtually no influence on the predictive strength of
the model (Fig. 3).
DISCUSSION
In this study, we analyze for the first time the impact of SES
implantation on the early outcomes of patients with ACS.
Compared with conventional bare stents, utilization of SES
in unselected patients with acute MI or unstable angina was
observed to be safe at 30 days, with similar rates of
procedural success and early adverse events.
Patients treated with SES differed in some aspects from
patients in the control group. Control patients presented
more rescue angioplasty for failed thrombolysis (instead of
primary angioplasty), which could have increased the risk of
events in this group. Conversely, SES patients were more
frequently treated for bifurcation lesions, a well-known risk
factor for periprocedural complications (21,22). Moreover,
glycoprotein IIb/IIIa inhibitors were less commonly used in
patients treated with SES, which may have exposed these
patients to a higher procedural risk (23). It seems unlikely
that the lower utilization of glycoprotein IIb/IIIa blockers in
this group could be explained by a lower risk profile
perceived during the procedure because both the control and
SES populations were equally composed predominantly of
patients with acute MI or high-grade unstable angina, with
no significant difference in their diabetic status. Neverthe-
less, after adjusting for baseline and procedural differences,
the type of stent used, either bare or SES, was not
significantly associated with the occurrence of early adverse
events.
Recently, sirolimus has been reported to reduce endo-
thelium-dependent relaxation in vitro in a porcine model,
although the authors did not rule out an effect of the drug
vehicle (8). Additionally, sirolimus has been reported to
increase platelet aggregation and secretion in transplant
recipients (11). However, recent studies have demonstrated
that this drug efficiently blocks the synthesis of Bcl-3, a
regulatory protein expressed when platelets adhere to colla-
gen via integrin IIb3 (9,10,24). Regardless of these con-
tradictory laboratory findings, SES was not associated with
clinically relevant device-related complications in our series,
with no modification of the risk profile for procedural failure
or event occurrence.
Patients treated with SES presented a similar timing of
Table 2. Incidence of Adverse Events at 30 Days in Patients





(n  198) p Value
Death, % 3.0 3.0 1.0
Nonfatal MI, % 1.0 3.0 0.17
TLR, % 2.7 1.0 0.33
TVR (includes TLR), % 2.7 1.0 0.33
Total MACE, % 6.6 6.1 0.85
Thrombotic stent occlusion, % 1.7 0.5 0.41
MACE  major adverse cardiac event; MI  myocardial infarction; SES 
sirolimus-eluting stent; TLR  target lesion revascularization; TVR  target vessel
revascularization.
Figure 1. Cumulative major adverse cardiac events (MACE) rate (death, nonfatal myocardial infarction, or re-intervention) during the first month for
control patients (bare stent) and patients treated with sirolimus-eluting stents (SES). Note that 50% of events occurred during the first week in both
groups.
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postprocedural complications compared with control pa-
tients, with most events occurring in the first days after the
procedure, a typical pattern previously reported after bare
stent implantation (4,5). In this context, a relatively delayed
hazardous effect of the drug leading to an increase in “late”
thrombotic complications after the first week was not
observed in our patients.
STUDY LIMITATIONS
The present investigation suffers from the inherent limita-
tions of a nonrandomized trial, which explains some unbal-
ance in the baseline characteristics among the treatment
groups. However, the study population is representative of
the “real world” of interventional cardiology, with findings
more readily applicable to daily clinical practice. Postproce-
dure cardiac markers were not collected routinely for all
patients (available for 42% of control patients and 46% of
patients in the SES subgroup [p  NS]). This was justified
by the fact that high-grade enzymatic elevations, those with
proven prognostic impact (15,16), rarely occur “unnoticed”
in asymptomatic patients. When comparing patients with
and without postprocedure enzymes collected, the 30-day
death rate was 7.1% versus 0% (p  0.001) and the
re-intervention rate was 4.7% versus 0% (p  0.001),
reflecting the low-risk nature of patients for whom cardiac
markers were not measured. Similarly, the relatively low
frequency of utilization of glycoprotein IIb/IIIa inhibitors in
our study reflects the current practice of administration of
these drugs in several countries worldwide (25). Risk strat-
ification was based mainly on clinical characteristics. Al-
though laboratorial tests are known to add important
prognostic information, the validated Braunwald classifica-
tion for unstable angina applied in the present study
provides a powerful clinical tool for individual risk assess-
ment (14).
CONCLUSIONS
Sirolimus-eluting stent implantation for patients with ACS
was safe, with early outcomes comparable to conventional
bare metal stents. Maintenance of the excellent short-term
results already achieved with the current techniques is
crucial for the validation of SES as a useful strategy in the
treatment of complex cases, such as those commonly found
in daily practice. Further evaluation in the context of
randomized trials is warranted to confirm the results ob-
served in the present study.
Figure 2. Multivariate independent predictors of 30-day major adverse cardiac events (MACE) rate (death, nonfatal myocardial infarction, and
re-intervention) derived from the final logistic regression model. The odds ratios (OR) are shown on logarithmic scale together with their 95% confidence
interval (CI).
Figure 3. Comparison of the strength (chi-square values) for the prediction
of 30-day major adverse cardiac events (MACE) rate (death, nonfatal
myocardial infarction, and re-intervention) of multivariate models. Model
1 is the final model selected in the logistic regression analysis and included
the variables displayed in Figure 2. The forced inclusion of sirolimus-
eluting stent (SES) utilization (Model 2) did not enhance the predictive
strength of the model, as reflected by the negligible change in the
chi-square values.
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